Loading…
Erythropoietin Resistance in Patients with Chronic Kidney Disease: Current Perspectives
Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin defciency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it...
Saved in:
Published in: | International journal of nephrology and renovascular disease 2020-01, Vol.13, p.231-237 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Anemia is a frequent complication of chronic kidney disease, and its primary cause is erythropoietin defciency. After diagnosis, treatment begins with administration of an erythropoiesis-stimulating agent (ESA). However, some patients present with resistance to ESA, which needs to be reversed, as it can increase the risk of death in patients with kidney disease. Therefore, we provide a discussion of the current literature regarding the factors that can modify the response to this class of drugs and the strategies that can be considered to optimize the benefts of treating anemia. Keywords: anemia, chronic kidney disease, erythropoietin, drug resistance |
---|---|
ISSN: | 1178-7058 1178-7058 |
DOI: | 10.2147/IJNRD.S239151 |